{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:07:00Z","timestamp":1776899220316,"version":"3.51.2"},"reference-count":88,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,28]]},"abstract":"<jats:p>Stein and Martin provide a review of the thrombotic and bleeding complications of myeloproliferative neoplasms and provide a roadmap for appropriate therapy.<\/jats:p>","DOI":"10.1182\/blood.2019001318","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T17:08:47Z","timestamp":1574960927000},"page":"1902-1911","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms"],"prefix":"10.1182","volume":"134","author":[{"given":"Brady L.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlyn","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019112812083867700_B1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"2019112812083867700_B2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019112812083867700_B3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"2019112812083867700_B4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2019112812083867700_B5","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis [published online ahead of print 23 May 2019]","author":"Ferrari","journal-title":"Haematologica"},{"issue":"26","key":"2019112812083867700_B6","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of Thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019112812083867700_B7","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"2019112812083867700_B8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"2019112812083867700_B9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-030-20315-3_11","article-title":"Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms","volume-title":"Thrombosis and Hemostasis in Cancer","author":"Sankar","year":"2019"},{"issue":"1","key":"2019112812083867700_B10","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2019112812083867700_B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clml.2018.08.020","article-title":"Influence of blood count, cardiovascular risks, inherited thrombophilia, and JAK2 V617F burden allele on type of thrombosis in patients with Philadelphia chromosome negative myeloproliferative neoplasms","volume":"19","author":"Horvat","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2019112812083867700_B12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2019112812083867700_B13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019112812083867700_B14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019112812083867700_B15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2019112812083867700_B16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019112812083867700_B17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"2019112812083867700_B18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019112812083867700_B19","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019112812083867700_B20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019112812083867700_B21","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2019112812083867700_B22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"2019112812083867700_B23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2019112812083867700_B24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2018.205989","article-title":"New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches","volume":"104","author":"Bar-Natan","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2019112812083867700_B25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2019112812083867700_B26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019112812083867700_B27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2019112812083867700_B28","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through \u03b21\/\u03b22 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J Clin Invest"},{"issue":"436","key":"2019112812083867700_B29","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"issue":"11","key":"2019112812083867700_B30","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2V617F mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"issue":"2","key":"2019112812083867700_B31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"2019112812083867700_B32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"Chu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"2019112812083867700_B33","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"2019112812083867700_B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-018-0078-3","article-title":"The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"2019112812083867700_B35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.6004\/jnccn.2018.7073","article-title":"Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction?","volume":"16","author":"Sankar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"34","key":"2019112812083867700_B36","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019112812083867700_B37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.6004\/jnccn.2016.0133","article-title":"Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era","volume":"14","author":"Kander","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2019112812083867700_B38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2019112812083867700_B39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2019112812083867700_B40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2019112812083867700_B41","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2019112812083867700_B42","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2018-99-115129","article-title":"Long-term efficacy and safety (5 years) in RESPONSE, a phase 3 study comparing ruxolitinib (rux) with best available therapy (BAT) in hydroxyurea (HU)-resistant\/intolerant patients (pts) with polycythemia vera (PV) [abstract]","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2019112812083867700_B43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019112812083867700_B44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00277-013-1683-7","article-title":"Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide","volume":"92","author":"Hern\u00e1ndez-Boluda","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"2019112812083867700_B45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019112812083867700_B46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2014.04.032","article-title":"Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey","volume":"134","author":"Ellis","year":"2014","journal-title":"Thromb Res"},{"issue":"1","key":"2019112812083867700_B47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","article-title":"High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation","volume":"98","author":"Wille","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"2019112812083867700_B48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"Ianotto","year":"2017","journal-title":"Int J Hematol"},{"key":"2019112812083867700_B49","unstructured":"NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines) for myeloproliferative neoplasms , version 2.2019. www.nccn.org. Accessed 24 June 2019."},{"issue":"11","key":"2019112812083867700_B50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"2019112812083867700_B51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2014.03.040","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases","volume":"134","author":"Dentali","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"2019112812083867700_B52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11899-018-0446-x","article-title":"Splanchnic vein thrombosis in the myeloproliferative neoplasms","volume":"13","author":"Akpan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"25","key":"2019112812083867700_B53","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019112812083867700_B54","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019112812083867700_B55","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br J Haematol"},{"key":"2019112812083867700_B56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2018.05.007","article-title":"Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"167","author":"Li","year":"2018","journal-title":"Thromb Res"},{"issue":"3","key":"2019112812083867700_B57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"issue":"21","key":"2019112812083867700_B58","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019112812083867700_B59","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-014-2134-9","article-title":"The JAK2 46\/1 haplotype (GGCC) in myeloproliferative neoplasms and splanchnic vein thrombosis: a pooled analysis of 26 observational studies","volume":"93","author":"Li","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"2019112812083867700_B60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2011.03.024","article-title":"Sex modulation of the occurrence of JAK2 V617F mutation in patients with splanchnic venous thrombosis","volume":"128","author":"Colaizzo","year":"2011","journal-title":"Thromb Res"},{"issue":"7","key":"2019112812083867700_B61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"11","key":"2019112812083867700_B62","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2019112812083867700_B63","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo Clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2019112812083867700_B64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24614","article-title":"Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"92","author":"Pieri","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"2019112812083867700_B65","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ajh.24798","article-title":"Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension","volume":"92","author":"Reilly","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2019112812083867700_B66","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/liv.12816","article-title":"Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms","volume":"35","author":"Potthoff","year":"2015","journal-title":"Liver Int"},{"issue":"5","key":"2019112812083867700_B67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12185-015-1871-4","article-title":"Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort","volume":"102","author":"Kander","year":"2015","journal-title":"Int J Hematol"},{"issue":"10","key":"2019112812083867700_B68","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019112812083867700_B69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.2830200408","article-title":"The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases","volume":"20","author":"Buss","year":"1985","journal-title":"Am J Hematol"},{"issue":"12","key":"2019112812083867700_B70","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"2019112812083867700_B71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"8","key":"2019112812083867700_B72","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","article-title":"Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden","volume":"96","author":"Bertozzi","year":"2017","journal-title":"Ann Hematol"},{"issue":"2","key":"2019112812083867700_B73","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"2019112812083867700_B74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2019112812083867700_B75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2019112812083867700_B76","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"Hern\u00e1ndez-Boluda","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"2019112812083867700_B77","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2019112812083867700_B78","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","article-title":"Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)","volume":"95","author":"Appelmann","year":"2016","journal-title":"Ann Hematol"},{"issue":"1","key":"2019112812083867700_B79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00277-016-2826-4","article-title":"Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey","volume":"96","author":"Koren-Michowitz","year":"2017","journal-title":"Ann Hematol"},{"issue":"2","key":"2019112812083867700_B80","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","article-title":"Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey","volume":"111","author":"Ruggeri","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019112812083867700_B81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"key":"2019112812083867700_B82","article-title":"Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms [published online ahead of print 26 June 2018]","author":"Lapoirie","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"9","key":"2019112812083867700_B83","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1002\/ajh.25210","article-title":"Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera","volume":"93","author":"Bertozzi","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2019112812083867700_B84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"issue":"8","key":"2019112812083867700_B85","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019112812083867700_B86","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1182\/blood-2018-99-118299","article-title":"Pregnancy outcomes in patients with myeloproliferative neoplasms: a systematic review and meta-analysis [abstract]","volume":"132","author":"Maze","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019112812083867700_B87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/bloodadvances.2018026294","article-title":"Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis","volume":"3","author":"Setiadi","year":"2019","journal-title":"Blood Adv"},{"key":"2019112812083867700_B88","first-page":"510","article-title":"Myeloproliferative neoplasms. In: Cuker A, Altman JK, Gerds AT, Wun T, eds. American Society of Hematology Self-Assessment Program","author":"Stein","year":"2019"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1902\/1543079\/bloodbld2019001318c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/22\/1902\/1543079\/bloodbld2019001318c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T21:46:08Z","timestamp":1722116768000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/22\/1902\/428844\/From-BuddChiari-syndrome-to-acquired-von"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":88,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001318","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]}}}